Answers are grounded in this paper and cite their sources.
Highly active antiretroviral therapy (HAART) has been linked to increases in plasma lipids. To determine the risk of cardiovascular disease, 23 patients with a stroke or myocardial infarction (separated according to the year of event development; 1994–1997, n = 9 versus 1998–2000, n = 14) were identified and compared. ‘Classic’ risk factors were frequently detected, and seemed to be more deeply associated in the short term. HAART conferred longer survival, even after the development of cardiovascular complications. The use of highly active antiretroviral therapy (HAART) for the treatment of HIV-1 infection has been linked to increases in plasma lipids. The risk of the development of premature atherosclerosis remains to be established. Increases in plasma concentrations of LDL and triglycerides may contribute to the appearance of coronary artery disease [1]. Triglycerides may increase the cardiovascular risk by increasing plasma viscosity [2]. ‘Traditional’ risk factors (e.g. cigarette smoking, alcohol consumption, dyslipemia) have frequently been described in the European HIV-infected population. Accordingly, there is an urgent need to assess the incidence of cardiovascular disease (CVD), to determine the relative contribution of various therapeutic regimens to its development, and to identify factors contributing to such side-effects. We have identified all the HIV-infected adults who developed a vascular event (stroke or myocardial infarction; MI) in a tertiary centre located in Madrid, Spain, in a 7-year period. For the purpose of analysis, the patients were separated into two groups according to the year in which the vascular complication developed, and the availability of HAART (1994–1997 versus 1998–2000). In the second period, all the patients were receiving HAART, and therefore the event could have been treatment linked. The mean number of patients on follow-up were 1489 versus 1558 in the first and second periods, respectively. A total of 23 patients were identified and their clinical charts were reviewed. The main characteristics of the study population can be seen in Table 1. Most patients were young, male, and current heavy smokers. Nine patients were diagnosed in the first period versus 14 patients in the HAART period. More strokes were detected in the pre-HAART era, with a well-balanced number of episodes of MI and central nervous system (CNS) complications in the second period. All patients had at least one ‘classic’ risk factor, with a mean of 1.55 risk factors per patient (1994–1997 period) and 2.3 (1998–2000 period). Diabetes mellitus and overweight were only detected in the second period, as well as age greater than 65 years. These facts could be related to the use of HAART, which undoubtedly confers longer and better survival to HIV-infected individuals. In the second period, all patients received HAART. Eight patients started HAART (median time 29 months) before the vascular event occurred. Of note was the fact that HAART was administered after CVD in five patients, and none developed additional events. The survival in the group receiving HAART was higher. Only one patient died, as a result of a non HIV-related condition (a 74-year-old man with an extensive stroke).Table 1: Demographic, epidemiological, clinical, therapeutic, and laboratory features of the 131 HIV-infected patients who showed at least one altered creatine phosphokinase assay in a 9-month period, compared with those of 393 patients randomly selected from the same patient cohort, who did not show any muscle enzyme abnormality in the same time period.The major finding of this study is that the risk of vascular disease in HIV-infected patients on HAART seems not to be increased with respect to that of untreated HIV-infected patients, at least in the short term. Moreover, the administration of HAART confers longer survival, even after the development of cardiovascular complications. Since 1998, when anecdotal reports of premature CVD associated with new therapies were described [3–5], it has been debated whether the lipid perturbations that exist during HAART have a significant impact on the development of CVD in these patients. There are different reasons that support a presumably higher incidence of CVD in HIV-infected patients on HAART. First, the prolongation of survival may lead to an increased exposure to pre-existing cumulative cardiovascular risk factors, mainly smoking, the prevalence of which is particularly high in this population. Second, protease inhibitor (PI)-containing regimens are associated with a higher risk of dyslipemia and insulin resistance. Third, various inflammatory and immunological factors associated with HIV infection may contribute to accelerated atherosclerosis or thrombosis. It is not surprising that premature atherosclerosis within the femoral or carotid arteries, visualized with high resolution ultrasound imaging, has been detected more frequently in the HIV-infected population [6]. A recent communication highlighted that the risk of MI appears to be increase by several-fold among HIV-infected patients being treated with PI [7]. Despite these arguments, controversy exists as to whether HAART is linked with CVD. In accordance with our results, one of the major findings in the above-mentioned study [6] was the lack of a link with the use of PI-based regimens, but rather with ‘classic’ cardiovascular risk factors. Similarly, PI were not associated with an increased risk of CVD in another case–control study [8]. Bozzette et al. [9] reported on a large group of contributing patients (n = 36 766, between January 1993 and June 2001), in which no association was found between an increased risk of any cardiovascular events and any antiretroviral therapy. They concluded that the large increase in antiretroviral use correlated with sharp declines in overall mortality and slight declines in cardiovascular events [9]. There are some limitations in our study. Most retrospective analyses are subject to ascertainment bias. The number of patients included is small. Longer exposures to new combination therapies could reveal an association with an increased risk of vascular complications. Moreover, the association of classic risk factors (e.g. dyslipemia, diabetes mellitus) might partly reflect the effects of PI, and their long-term consequences remain to be clarified. In summary, our results suggest that ‘traditional’ risk factors are more deeply associated with cardiovascular complications in HIV-infected patients than new combination therapies. No significant association was found between HAART and the development of CVD in the short term. There is no doubt that the question is important and will receive much more attention in the near future. Additional larger longitudinal cohort studies will be needed in order to confirm or refute our findings.
No takes yet. Share an insight, caveat, or question.
Dronda et al. (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: